1 week Ago By Defense World Staff
Equities research analysts at StockNews.com assumed coverage on shares of Akari Therapeutics ( NASDAQ:AKTX – Get Free Report ) in a research report issued to clients and investors on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Akari Therapeutics Trading Up 8.3 % Akari Therapeutics stock opened at $1.31 on Friday.
Akari Therapeutics has a 52 week low of $0.90 and a 52 week high of $4.40.
The business’s 50-day simple moving average is $1.53 and its 200-day simple moving average is $2.66.
About Akari Therapeutics ( Get Free Report ) See Also Five stocks we like better than Akari Therapeutics The Role Economic Reports Play in a Successful Investment Strategy Quantum Opportunity: Skywater Technology’s Long-Term Potential How to Evaluate a Stock Before Buying Nebius Group: The Rising Star in AI Infrastructure What is the Shanghai Stock Exchange Composite Index? MarketBeat Week in Review – 12/30 – 1/03 Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
